The efficacy of platinum-based chemotherapy for immune checkpoint inhibitor-resistant advanced melanoma
Author:
Affiliation:
1. Department of Dermatologic Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan;
2. Department of Dermatology, Faculty of Medicine and Graduate School of Medicine Hokkaido University, Sapporo, Japan
Publisher
Informa UK Limited
Subject
Radiology Nuclear Medicine and imaging,Oncology,Hematology,General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2018.1541252
Reference12 articles.
1. Nivolumab in Previously Untreated Melanoma withoutBRAFMutation
2. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
3. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
4. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients
5. Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non–Small Cell Lung Cancer
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Is There a Current Role for Combination Chemotherapy or High-Dose Interleukin 2 in Melanoma?;The Cancer Journal;2024-03
2. Chemotherapie nach Progress unter Immuncheckpoint-Inhibition beim metastasierten malignen Melanom: Fallbericht und Literaturübersicht;TumorDiagnostik & Therapie;2023-11
3. Successful treatment with carboplatin and paclitaxel in melanoma progression after immune-related adverse events;Immunotherapy;2023-09
4. Chemotherapie nach Progress unter Immuncheckpoint-Inhibition beim metastasierten malignen Melanom: Fallbericht und Literaturübersicht;Deutsche Zeitschrift für Onkologie;2023-03
5. Novel “SMARTer” Clinical Trial Design Improves Odds of Approval and Can Reduce Study Size By 80%: Modeling Use of a ctDNA “Optimizing Diagnostic” for Early Therapy Switching in Immuno-Oncology Trials;2023-02-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3